Quantinno Capital Management LP Increases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Quantinno Capital Management LP grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 13.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 216,461 shares of the company’s stock after purchasing an additional 25,349 shares during the period. Quantinno Capital Management LP’s holdings in Teva Pharmaceutical Industries were worth $6,520,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Norges Bank purchased a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $1,098,060,000. WCM Investment Management LLC raised its position in Teva Pharmaceutical Industries by 191.4% during the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after buying an additional 26,813,522 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after buying an additional 7,255,083 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after acquiring an additional 6,878,304 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after acquiring an additional 5,917,423 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TEVA. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Barclays boosted their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Truist Financial increased their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Eliyahu Sharon Kalif sold 153,251 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the sale, the executive vice president directly owned 172,184 shares in the company, valued at approximately $6,131,472.24. This trade represents a 47.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $34.73 on Thursday. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $15.75 and a fifty-two week high of $37.35. The stock has a market cap of $39.94 billion, a PE ratio of 57.89, a price-to-earnings-growth ratio of 3.68 and a beta of 0.86. The firm’s fifty day simple moving average is $33.24 and its 200-day simple moving average is $32.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The firm had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.96 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.